Form 144 FATE THERAPEUTICS INC For: 9 January
- Investing.com
- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Fate Therapeutics Inc (FATE)
Fate Therapeutics Inc stock price live, this page displays NASDAQ FATE stock exchange data. View the FATE premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Fate Therapeutics Inc real time stock price chart below.
What Is the Fate Therapeutics Inc Stock Price Today?
The Fate Therapeutics Inc stock price today is 1.210.
What Is the Stock Symbol for Fate Therapeutics Inc?
The stock symbol for Fate Therapeutics Inc is "FATE."
What Stock Exchange Does Fate Therapeutics Inc Trade On?
Fate Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Fate Therapeutics Inc a Good Stock to Buy?
Determining whether Fate Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the FATE quote. (ISIN: US31189P1021)
What Is the Fate Therapeutics Inc Stock Price Today?
The Fate Therapeutics Inc stock price today is 1.210.
What Is the Stock Symbol for Fate Therapeutics Inc?
The stock symbol for Fate Therapeutics Inc is "FATE."
What Stock Exchange Does Fate Therapeutics Inc Trade On?
Fate Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Fate Therapeutics Inc a Good Stock to Buy?
Determining whether Fate Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the FATE quote. (ISIN: US31189P1021)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.200
1.280
52 wk Range
0.661
1.940
FATE is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.2001.280
52 wk Range
0.6611.940
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
FATE Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
4.944
Upside
+308.63%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
High shareholder yield
- Form 144 FATE THERAPEUTICS INC For: 29 December
- Investing.com
- Form 8K Fate Therapeutics Inc For: 13 November
- Investing.com
- Form 144 FATE THERAPEUTICS INC For: 9 January
- Investing.com
- Form 144 FATE THERAPEUTICS INC For: 29 December
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Buy
Fate Therapeutics Inc Company Profile
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company’s chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma; FT836 whiuch is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, and FT825 to treat solid tumors.It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Fate Therapeutics Inc SWOT Analysis
Promising Pipeline | Fate Therapeutics' FT819 and FT522 show encouraging results in treating SLE and B-cell lymphoma, potentially revolutionizing autoimmune disease therapy |
Financial Challenges | Despite strong clinical data, Fate operates at a loss with negative EPS projections, balancing a $330.5M cash reserve against ongoing R&D expenses |
Market Outlook | Analyst price targets range from $2 to $10, reflecting varied optimism about Fate's future. The biotech sector's positive outlook may favor growth |
Strategic Potential | Successful trials could position Fate as a leader in cellular therapies, attracting partnerships and expanding market opportunities in cancer and autoimmune diseases |
Fate Therapeutics Inc Earnings Call Summary for Q1/2024
- FT819 and FT522 cell therapies show promise in autoimmune diseases and B-cell lymphoma; first lupus patient treated in FT819 Phase I study
- FT825 enters Phase I study for solid tumors; company plans to achieve five clinical milestones in H2 2024
- $391 million in cash and investments at Q1 2024 end; projected 2024 GAAP operating expenses of $215-230 million
- Anticipated year-end cash balance over $270 million; consistent quarterly cash burn of $37-38 million expected
- Company to provide updates on first lupus patients treated with FT819 by year-end; exploring additional indications for cell therapies
Last Updated: 2024-05-13, 12:58 p/m
Read Full TranscriptCompare FATE to Peers and Sector
Metrics to compare | FATE | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipFATEPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.9x | −1.9x | −0.6x | |
PEG Ratio | −0.05 | 0.02 | 0.00 | |
Price/Book | 0.6x | 1.4x | 2.6x | |
Price / LTM Sales | 19.6x | 7.7x | 3.4x | |
Upside (Analyst Target) | 313.2% | 329.3% | 41.5% | |
Fair Value Upside | Unlock | 21.8% | 4.4% | Unlock |
Analyst Ratings
6 Buy
6 Hold
0 Sell
Ratings:
12 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 4.944
(+308.63% Upside)
Earnings
Latest Release
Nov 13, 2025
EPS / Forecast
-0.27 / -0.30
Revenue / Forecast
1.74M / 1.36M
People Also Watch
FAQ
What Is the Fate Therapeutics (FATE) Stock Price Today?
The Fate Therapeutics stock price today is 1.210
What Stock Exchange Does Fate Therapeutics Trade On?
Fate Therapeutics is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Fate Therapeutics?
The stock symbol for Fate Therapeutics is "FATE."
What Is the Fate Therapeutics Market Cap?
As of today, Fate Therapeutics market cap is 139.58M.
What Is Fate Therapeutics's Earnings Per Share (TTM)?
The Fate Therapeutics EPS (TTM) is -1.32.
When Is the Next Fate Therapeutics Earnings Date?
Fate Therapeutics will release its next earnings report on Mar 02, 2026.
From a Technical Analysis Perspective, Is FATE a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Fate Therapeutics Stock Split?
Fate Therapeutics has split 0 times.
How Many Employees Does Fate Therapeutics Have?
Fate Therapeutics has 181 employees.
What is the current trading status of Fate Therapeutics (FATE)?
As of Jan 25, 2026, Fate Therapeutics (FATE) is trading at a price of 1.210, with a previous close of 1.250. The stock has fluctuated within a day range of 1.200 to 1.280, while its 52-week range spans from 0.661 to 1.940.
What Is Fate Therapeutics (FATE) Price Target According to Analysts?
The average 12-month price target for Fate Therapeutics is USD4.944, with a high estimate of USD8 and a low estimate of USD2. 6 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +308.63% Upside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.